Holen Sie sich die Stockscreener-App
24.18
3.47%
-0.87
Handel nachbörslich:
24.18
Schlusskurs vom Vortag:
$25.05
Offen:
$25.07
24-Stunden-Volumen:
1.16M
Relative Volume:
1.39
Marktkapitalisierung:
$3.48B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-22.18
EPS:
-1.09
Netto-Cashflow:
$-402.10M
1W Leistung:
-23.43%
1M Leistung:
-12.36%
6M Leistung:
+17.89%
1J Leistung:
+28.89%
1-Tages-Spanne:
$24.06
$25.35
1-Wochen-Bereich:
$24.06
$31.47
52-Wochen-Spanne:
$14.56
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8548
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| DNLI | 24.18 | 3.48B | 340.81M | -419.65M | -402.10M | -1.09 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.3%Here's What Happened - MarketBeat
Denali Has A Neurodegenerative Edge Despite Market Skepticism (NASDAQ:DNLI) - Seeking Alpha
Los Angeles Capital Management LLC Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely - Yahoo Finance
State of New Jersey Common Pension Fund D Sells 25,613 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Capital Research Global Investors Expands Stake in Denali Therap - GuruFocus.com
FMR LLC Expands Stake in Denali Therapeutics Inc - GuruFocus.com
BofA raises Denali Therapeutics target to $34 on BLA plans By Investing.com - Investing.com Canada
Denali Therapeutics executive sells shares worth $465,286 By Investing.com - Investing.com Australia
Denali Therapeutics executive sells shares worth $465,286 - Investing.com
Baillie Gifford & Co. Sells 417,709 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Principal Financial Group Inc. Increases Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics stock soars to 52-week high of $32.17 - Investing.com India
Denali Therapeutics stock soars to 52-week high of $32.17 By Investing.com - Investing.com Canada
Learn to Evaluate (DNLI) using the Charts - Stock Traders Daily
Denali Therapeutics (NASDAQ:DNLI) Reaches New 12-Month HighStill a Buy? - MarketBeat
Wedbush Cuts Earnings Estimates for Denali Therapeutics - Defense World
Brokers Issue Forecasts for DNLI Q1 Earnings - MarketBeat
HC Wainwright Has Bearish Forecast for DNLI FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for DNLI FY2024 Earnings - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Denal - GuruFocus.com
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging - Yahoo Finance
HC Wainwright Issues Pessimistic Forecast for DNLI Earnings - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Given "Buy" Rating at HC Wainwright - MarketBeat
Denali Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com UK
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Denali Therapeutics director Vicki Sato sells $83,375 in stock - Investing.com India
abrdn plc Sells 209,356 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.22 Average Price Target from Analysts - MarketBeat
Zacks Research Issues Pessimistic Forecast for DNLI Earnings - MarketBeat
Denali Therapeutics CEO Ryan Watts sells shares worth $1.1 million - Investing.com
Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells 40,000 Shares of Stock - MarketBeat
(DNLI) Investment Analysis and Advice - Stock Traders Daily
The five-year returns have been notable for Denali Therapeutics (NASDAQ:DNLI) shareholders despite underlying losses increasing - Simply Wall St
Denali Therapeutics Inc (DNLI) stock on the rise: An overview - US Post News
Denali Therapeutics Inc (DNLI)’s Market Momentum: Closing Strong at 26.83, Down -4.18 - The Dwinnex
This trade activity should not be overlooked: Denali Therapeutics Inc (DNLI) - SETE News
Denali Therapeutics Inc (DNLI) receives a Mkt perform rating from Raymond James - Knox Daily
Denali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $28.00 at JPMorgan Chase & Co. - Defense World
Hunter Syndrome Therapeutic Market Is in Huge Demand:Takeda, Denali Therapeutics, ArmaGen, Inventiva, Green Cross Corp, – IndiaPolitics.com - IndiaPolitics.com
Denali Therapeutics shares hold steady from BTIG By Investing.com - Investing.com South Africa
Denali Therapeutics (NASDAQ:DNLI) Shares Down 3.8% on Analyst Downgrade - MarketBeat
Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now - Insider Monkey
Denali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Update - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Trading 6.4% HigherTime to Buy? - MarketBeat
Sanofi, Denali face trial setback for neuro drug (NASDAQ:DNLI) - Seeking Alpha
JPMorgan Chase & Co. Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $28.00 - MarketBeat
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):